Abstract:Cancer immunotherapy is a treatment method that activates or enhances the autoimmune response of the body to fight tumor growth and metastasis, has fewer toxic side effects and a longer-lasting efficacy than radiotherapy and chemotherapy, and has become an important means for the clinical treatment of cancer. However, clinical results from immunotherapy have shown that most patients lack responsiveness to immunotherapy and cannot benefit from this treatment strategy. The tumor microenvironment (TME) plays a critical role in the response to immunotherapy. The TME typically prevents effective lymphocyte activation, reducing their infiltration, and inhibiting the infiltration of effector T cells. According to the characteristic differences between the TME and normal tissues, various nanoplatforms with TME targeting and regulation properties have been developed for more precise regulation of the TME and have the ability to codeliver a variety of active pharmaceutical ingredients, thereby reducing systemic toxicity and improving the therapeutic effect of antitumor. In addition, the precise structural design of the nanoplatform can integrate specific functional motifs, such as surface-targeted ligands, degradable backbones, and TME stimulus-responsive components, into nanomedicines, thereby reshaping the tumor microenvironment, improving the body's immunosuppressive state, and enhancing the permeability of drugs in tumor tissues, in order to achieve controlled and stimulus-triggered release of load cargo. In this review, the physiological characteristics of the TME and the latest research regarding the application of TME-regulated nanoplatforms in improving antitumor immunotherapy will be described. Furthermore, the existing problems and further applications perspectives of TME-regulated platforms for cancer immunotherapy will also be discussed.

Research Progress in Tumor Targeted Immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

The Past, Present and Future of Immunotherapy Against Tumor.

Research Progress on Tumor-Targeting Immunoconjugate

The New Progress in Cancer Immunotherapy

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy.

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Nanoparticles breakthroughs tumor treatment limitations by regulating tumor immune microenvironment to enhance tumor immunotherapy efficacy

Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment

Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia

Research advances of targeted therapy of cancer

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress

Combined with Interventional Therapy, Immunotherapy Can Create a New Outlook for Tumor Treatment.